Journal
NANOMEDICINE
Volume 3, Issue 2, Pages 247-265Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/17435889.3.2.247
Keywords
biodegradable; brain cancer; breast cancer; imaging analysis; multiple antibodies; multiple drug delivery; multitargeting; Polycefin; poly(malic acid); tumor angiogenesis
Funding
- NCI NIH HHS [R01 CA123495-03, CA123495, R01 CA123495] Funding Source: Medline
- NCRR NIH HHS [M01 RR000425, M01 RR00425] Funding Source: Medline
- NEI NIH HHS [EY13431, R01 EY013431-07, R01 EY013431] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [R01CA123495] Funding Source: NIH RePORTER
- NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000425] Funding Source: NIH RePORTER
- NATIONAL EYE INSTITUTE [R01EY013431] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Nanoconjugates are emerging as promising drug-delivery vehicles because of their multimodular structure enabling them to actively target discrete cells, pass through biological barriers and simultaneously carry multiple drugs of various chemical nature. Nanoconjugates have matured from simple devices to multifunctional, biodegradable, nontoxic and nonimmunogenic constructs, capable of delivering synergistically functioning drugs in vivo. This review mainly concerns the Polycefin family of natural-derived polymeric drug-delivery devices as an example. This type of vehicle is built by hierarchic conjugation of functional groups onto the backbone of poly(malic acid), an aliphatic polyester obtained from the microorganism Physarum polycephalum. Particular Polycefin variants target human brain and breast tumors implanted into animals specifically and actively and could be detected easily by noninvasive imaging analysis. Delivery of antisense oligonucleotides to a tumor-specific angiogenic marker using Polycefin resulted in significant inhibition of tumor angiogenesis and increase of animal survival.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available